evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%

Canakinumab vs triamcinolone acetonide

Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout

Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Canakinumab vs triamcinolone acetonide

Global assessment of treatment success · acute gout

Canakinumab probably leads to higher participant global assessment of response to treatment: good or… compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review

Canakinumab vs triamcinolone acetonide

Risk for at least one adverse event per patient · acute gout

Canakinumab probably leads to higher participants with at least 1 AE (all canakinumab doses) compared with triamcinolone acetonide (moderate certainty).

1 finding from 1 review